Maxim Group set a $6.00 target price on Sophiris Bio (NASDAQ:SPHS) in a research report report published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

SPHS has been the subject of several other research reports. ValuEngine upgraded shares of Sophiris Bio from a hold rating to a buy rating in a research note on Thursday, December 13th. HC Wainwright set a $10.00 price target on shares of Sophiris Bio and gave the company a buy rating in a research report on Wednesday, November 14th.

Shares of Sophiris Bio stock opened at $1.23 on Monday. The stock has a market capitalization of $62.33 million, a P/E ratio of -3.08 and a beta of 1.91. Sophiris Bio has a twelve month low of $1.12 and a twelve month high of $4.05. The company has a debt-to-equity ratio of 1.30, a quick ratio of 4.16 and a current ratio of 4.16.

Sophiris Bio (NASDAQ:SPHS) last released its earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.03. Sell-side analysts forecast that Sophiris Bio will post -0.54 EPS for the current year.

In other Sophiris Bio news, insider Randall E. Woods purchased 10,000 shares of Sophiris Bio stock in a transaction on Wednesday, September 19th. The shares were bought at an average price of $2.63 per share, with a total value of $26,300.00. Following the completion of the acquisition, the insider now directly owns 10,000 shares of the company’s stock, valued at $26,300. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 5.50% of the company’s stock.

An institutional investor recently raised its position in Sophiris Bio stock. Northern Trust Corp lifted its holdings in Sophiris Bio Inc (NASDAQ:SPHS) by 293.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,600 shares of the biopharmaceutical company’s stock after acquiring an additional 60,092 shares during the period. Northern Trust Corp owned approximately 0.27% of Sophiris Bio worth $226,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.01% of the company’s stock.

Sophiris Bio Company Profile

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Further Reading: How to invest in a bear market

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.